Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496131 · ClinicalTrials.gov registry record · Phase 2
Tecemotide (L-BLP25) in Prostate Cancer
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01496131: Completed Phase 2 study, sponsored by EMD Serono.
NCT01496131 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01496131, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
Primary Outcome
MUC1-specific systemic immune response was measured by intracellular cytokine antigen specific staining following a period of in vitro stimulation (IVS) with overlapping 15-mer peptide pools encoding the tumor-associated antigen (TAA) MUC-1. Baseline was defined as the measurement taken prior to the first dose of study medication (Day 1).
Interventions
- DRUG Cyclophosphamide
- DRUG Goserelin
- RADIATION Radiation therapy
- DRUG Tecemotide (L-BLP25)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-10-24 |
| Est. Completion | 2016-11-25 |
| Phase | Phase 2 |
What the finished NCT01496131 record still lists
NCT01496131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT01496131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01496131 about?
NCT01496131 is a clinical study titled "Tecemotide (L-BLP25) in Prostate Cancer". This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
What is the current status of trial NCT01496131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2011-10-24. Estimated completion is 2016-11-25.
What interventions are being tested in trial NCT01496131?
The interventions under investigation include: Cyclophosphamide (DRUG), Goserelin (DRUG), Radiation therapy (RADIATION), Tecemotide (L-BLP25) (DRUG).
Who is sponsoring clinical trial NCT01496131?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01496131's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI